XML 38 R29.htm IDEA: XBRL DOCUMENT
v3.23.2

Notes to the Consolidated Statements of Operations - Additional Information (Details) - EUR (€) € in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022
Notes to the Consolidated Statements of Operations |  |  |  |
Revenue recognized | € 7,579 | € 20,146 | € 14,708 | € 44,519
Milestone revenues |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |
Revenue recognized |  |  | 755 | 5,321
Additional development milestone payments |  | 10,000 |  |
Development milestone payment included in contract liabilities | 2,989 |  | 2,989 |
GSK | Belgium |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |
Revenue recognized | € 6,283 | € 19,295 | € 12,756 | € 43,041

X
- Definition The amount of additional development milestone payment received. + References No definition available. + Details
Name: | cvac_AdditionalDevelopmentMilestonePaymentsReceived
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of development milestone payment included in contract liabilities + References No definition available. + Details
Name: | cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_BE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |